Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 144807 + ketoconazole
- Development stage
- Discontinued
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BI 144807 + ketoconazole refers to a clinical pharmacokinetic study regimen rather than a fixed-dose combination drug product. BI 144807 (also known as AKST4290 or ALK4290) is an orally active small molecule antagonist of the C-C chemokine receptor type 3 (CCR3), which was originally developed by Boehringer Ingelheim and later licensed to Alkahest. It was investigated for the treatment of neovascular age-related macular degeneration (wet AMD) and asthma. Ketoconazole, a potent inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme, was co-administered in clinical trials (such as NCT01707940) to evaluate the influence of CYP3A4 inhibition on the pharmacokinetics, safety, and tolerability of BI 144807 in healthy subjects. The development of BI 144807 has been discontinued.
- Other names
- AKST4290 + ketoconazoleALK4290 + ketoconazole
02
Targets
CYP3A4 (Cytochrome P450 3A4)CYP51A1 (Sterol 14α-demethylase)
Beyond the preview
Go deeper on BI 144807 + ketoconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 144807 + ketoconazole.